Altered Tissue Distribution and Elimination of Amikacin Encapsulated in Unilamellar, Low-Clearance Liposomes (MiKasome®)

• Published in: Pharmaceutical research Vol. 15; no. 11; pp. 1775 - 1781
• Main Authors: Fielding, Robert M., Lewis, Ramilla O., Moon-McDermott, Lotus
• Format: Journal Article
• Language: English
• Published: New York, NY Springer 01.11.1998; Springer Nature B.V
• Subjects: Amikacin - administration & dosage; Amikacin - blood; Amikacin - pharmacokinetics; Animals; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Biological and medical sciences; Drug Carriers; General pharmacology; Liposomes; Male; Medical sciences; Metabolic Clearance Rate; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Rats; Rats, Sprague-Dawley; Tissue Distribution; Urine; Pharmaceutical technology; Intravenous administration; Amikacin; Rat; Rodentia; Elimination; Liposome; Blood plasma; Vertebrata; Antibiotic; Mammalia; Aminoglycoside; Animal; Distribution; Dosage form; Antibacterial agent; Pharmacokinetics

Amikacin in small unilamellar liposomes (MiKasome) has prolonged plasma residence (half-life > 24hr) and sustained efficacy in Gram-negative infection models. Since low-clearance liposomes may be subject to a lower rate of phagocytic uptake, we hypothesized this formulation may enhance amikacin d...